References
- Proal AD, VanElzakker MB. Long Covid or post-acute sequelae of
COVID-19 (PASC): An overview of biological factors that may contribute
to persistent symptoms. Frontiers in Microbiology. 2021;12.
doi:10.3389/fmicb.2021.698169
- Yong SJ. Long Covid or post-covid-19 syndrome: Putative
pathophysiology, risk factors, and treatments. Infectious Diseases.
2021;53(10):737–54. doi:10.1080/23744235.2021.1924397
- Argento E, Christie D, Mackay L, Callon C, Walsh Z.
Psychedelic-assisted psychotherapy after COVID-19: The therapeutic
uses of Psilocybin and MDMA for pandemic-related mental health
problems. Frontiers in Psychiatry. 2021;12.
doi:10.3389/fpsyt.2021.716593
- Kurtz JS, Patel NA, Gendreau JL, Yang C, Brown N, Bui N, et al. The
use of psychedelics in the treatment of medical conditions: An
analysis of currently registered psychedelics studies in the American
Drug Trial Registry. Cureus. 2022; doi:10.7759/cureus.29167
- Herrera JE, Niehaus WN, Whiteson J, Azola A, Baratta JM, Fleming TK,
et al. Multidisciplinary collaborative consensus guidance statement on
the assessment and treatment of fatigue in postacute sequelae of
sars‐cov‐2 infection patients. PM&R. 2021;13(9):1027–43.
doi:10.1002/pmrj.12684
- Davis HE, McCorkell L, Vogel JM, Topol EJ. Long covid: Major findings,
mechanisms and recommendations. Nature Reviews Microbiology.
2023;21(3):133–46. doi:10.1038/s41579-022-00846-2
- Gattuso JJ, Perkins D, Ruffell S, Lawrence AJ, Hoyer D, Jacobson LH,
et al. Default mode network modulation by psychedelics: A systematic
review. International Journal of Neuropsychopharmacology.
2022;26(3):155–88. doi:10.1093/ijnp/pyac074
- Kapoor A, Mahajan G, Kapur A. State of brain networks in long covid:
Post mild to moderate acute COVID-19 disease. SSRN Electronic Journal.
2022;1–26. doi:10.2139/ssrn.4309672
- Martin DA, Nichols CD. The effects of hallucinogens on gene
expression. Behavioral Neurobiology of Psychedelic Drugs.
2017;137–58. doi:10.1007/7854_2017_479